Chevy Chase Trust Holdings LLC Lowers Stock Holdings in Humana Inc. (NYSE:HUM)

Chevy Chase Trust Holdings LLC lessened its position in Humana Inc. (NYSE:HUM) by 1.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 65,378 shares of the insurance provider’s stock after selling 1,230 shares during the period. Chevy Chase Trust Holdings LLC’s holdings in Humana were worth $20,708,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in HUM. Creative Financial Designs Inc. ADV grew its stake in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 61 shares during the last quarter. CarsonAllaria Wealth Management Ltd. increased its position in shares of Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares in the last quarter. Atwood & Palmer Inc. acquired a new stake in shares of Humana in the third quarter valued at about $29,000. Ashton Thomas Securities LLC purchased a new stake in shares of Humana during the third quarter valued at approximately $31,000. Finally, Your Advocates Ltd. LLP increased its stake in Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Down 0.7 %

NYSE HUM opened at $291.10 on Wednesday. The firm’s 50 day moving average price is $274.51 and its two-hundred day moving average price is $328.34. The stock has a market cap of $35.05 billion, a price-to-earnings ratio of 25.78, a PEG ratio of 2.31 and a beta of 0.53. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $502.73. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Equities analysts anticipate that Humana Inc. will post 15.86 EPS for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a yield of 1.22%. Humana’s dividend payout ratio is presently 31.36%.

Analysts Set New Price Targets

HUM has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Jefferies Financial Group cut shares of Humana from a “buy” rating to a “hold” rating and dropped their target price for the stock from $519.00 to $253.00 in a report on Monday, October 7th. Royal Bank of Canada lowered their price objective on shares of Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Stephens reissued an “equal weight” rating and issued a $250.00 price target on shares of Humana in a report on Wednesday, October 9th. Finally, UBS Group lowered their price objective on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, October 4th. Twenty investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.